Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease

CARMIEL, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first Gaucher patient has been enrolled in the Company's phase IIa...
June 13, 2014 08:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year

CARMIEL, Israel, June 13, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today, that David Aviezer, Ph.D., has decided to retire after almost 12 years...
May 30, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 30, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Health Canada has granted regulatory approval to ELELYSO™...
May 28, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

CARMIEL, Israel, May 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that senior management will present at the Jefferies 2014 Global Healthcare...
May 22, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients

CARMIEL, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Australian Therapeutic Goods Administration (TGA) has granted...
May 07, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Oppenheimer 15th Annual Israeli Conference and the MIXiii Israel Innovation Conference, Biomed

CARMIEL, Israel, May 7, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer,...
April 23, 2014 08:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 Meeting

CARMIEL, Israel, April 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that preclinical data on oral antiTNF (PRX-106) was accepted for...
February 12, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014

CARMIEL, Israel, Feb. 12, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of...
February 06, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property

CARMIEL, Israel, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Brazilian National Institute of Industrial Property (INPI) has...
January 23, 2014 16:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada

CARMIEL, Israel, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Health Canada has completed a successful on-site evaluation of the...